Sign in

CIK 0001600620

  • Large accelerated filer

Aurinia Pharmaceuticals Inc.

Sign in to watch
Ticker
AUPH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
981231763
Phone
+1 250-744-2487
Business address
#140, 14315 - 118 AVENUE, EDMONTON, Alberta, Canada, T5L 4S6
  1. 3 Insider Initial Statement of Ownership
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Grant or award Director acquired 9,310 shares (grant or award)
  7. 4 Open-market sale Director sold 8,733 shares at $11.26 ($98,334)
  8. 4 Open-market sale Director sold 272 shares at $10.58 ($2,878)
  9. 4 Open-market sale Director sold 4,650 shares at $11.26 ($52,359)
  10. 4 Exercise or conversion Director acquired 8,733 shares (option exercise)
  11. 4 Open-market sale Director sold 4,818 shares at $11.26 ($54,251)
  12. 4 Open-market sale Director sold 4,815 shares at $11.26 ($54,217)
  13. 4 Open-market buy Director bought 20,000 shares at $8.91 ($178,284)
  14. 4 Grant or award EVP, Ops & Strategy acquired 271,134 shares (grant or award)
  15. 4 Open-market sale Chief Financial Officer sold 11,296 shares at $8.94 ($100,986)
  16. 4 Open-market sale EVP, General Counsel sold 19,402 shares at $8.94 ($173,454)
  17. 4 Grant or award Chief Business Officer acquired 107,202 shares (grant or award)
  18. 4 Grant or award Chief Commercial Officer acquired 170,188 shares (grant or award)
  19. 4 Grant or award EVP, Research and Development acquired 191,462 shares (grant or award)
  20. 4 Open-market sale Chief Executive Officer sold 32,750 shares at $8.94 ($292,785)

Page 5 of 10 · 184 filings